Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) EBIT: 2011-2025

Historic EBIT for Capricor Therapeutics (CAPR) over the last 13 years, with Sep 2025 value amounting to -$26.3 million.

  • Capricor Therapeutics' EBIT fell 102.03% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.0 million, marking a year-over-year decrease of 99.11%. This contributed to the annual value of -$42.6 million for FY2024, which is 76.78% down from last year.
  • Per Capricor Therapeutics' latest filing, its EBIT stood at -$26.3 million for Q3 2025, which was down 5.21% from -$25.0 million recorded in Q2 2025.
  • Capricor Therapeutics' 5-year EBIT high stood at -$1.3 million for Q4 2023, and its period low was -$26.3 million during Q3 2025.
  • Its 3-year average for EBIT is -$11.8 million, with a median of -$9.2 million in 2023.
  • Its EBIT has fluctuated over the past 5 years, first surged by 84.12% in 2023, then slumped by 500.79% in 2024.
  • Quarterly analysis of 5 years shows Capricor Therapeutics' EBIT stood at -$6.4 million in 2021, then declined by 26.44% to -$8.1 million in 2022, then soared by 84.12% to -$1.3 million in 2023, then slumped by 500.79% to -$7.7 million in 2024, then crashed by 102.03% to -$26.3 million in 2025.
  • Its EBIT stands at -$26.3 million for Q3 2025, versus -$25.0 million for Q2 2025 and -$7.7 million for Q4 2024.